Ningbo NewBay Medical Technology Signs an Exclusive License Agreement with Genentech to Develop and Commercialize GDC-0570

 Ningbo NewBay Medical Technology Signs an Exclusive License Agreement with Genentech to Develop and Commercialize GDC-0570

Ningbo NewBay Medical Technology Signs an Exclusive License Agreement with Genentech to Develop and Commercialize GDC-0570

Shots:

  • Genentech to receive up front, clinical, regulatory and commercial milestone along with royalties on sales of GDC-0570.
  • Ningbo NewBay to get an exclusive right to develop & commercialize GDC-0570 and allows it to accelerate the clinical development of investigational therapies
  • GDC-0570 is a small molecule Pan-PIM inhibitor, designed to show activity against MM and PC in a preclinical model

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Nature

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post